Menu
Search Close

News

Director Shareholdings

22nd July 2013

The Company has been informed that on 22 July 2013 certain Directors of the Company purchased ordinary shares in the Company as follows:

Director

No. of Shares purchased

Price at which shares purchased

No. of shares held pursuant to transaction (% of ISC following transaction)

David Evans

30,000

31.8 pence

5,130,000

(2.6%)

Kate Cornish-Bowden

45,000

32.0 pence

45,000

(0.02%)


For Further Information:

Scancell Holdings Plc
Dr Richard Goodfellow, Joint CEO                     + 44 (0) 74 2323 0 497
Professor Lindy Durrant, Joint CEO

Cenkos Securities: 
Camilla Hume                     +44 (0) 20 7397 8900
Stephen Keys

FTI Consulting 
Simon Conway                   +44 (0) 20 7831 3113
Mo Noonan


About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

Scancell to begin dosing in UK phase II trial of flagship skin cancer drug

Cliff Holloway, CEO of Scancell Holdings PLC (LON:SCLP), speaks to Proactive London's Andrew Scott after announcing they're to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug.

The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Pembrolizumab.

Thu, 25 Apr 2019 10:56:00

Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks

The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck

Thu, 25 Apr 2019 12:20:00

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia

Mon, 08 Apr 2019 08:20:00